Latest Pharma Insights
As Refund Claims Mount, Interest On IEEPA Tariff Payments Equals $650M A Month, $10Bn For 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
Henkel Buys Not Your Mother’s, Aveeno Collaborates With Mayo Clinic; Beauty Deals Roundup
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
Ascletis’s Phase II Obesity Data Support Monthly Or Longer Dosing For ASC30
Following promising obesity data for oral GLP-1 agonist ASC30, Ascletis unveiled data with a subcutaneous formulation showing efficacy as a monthly injection and possibly quarterly maintenance use.
Scrip - March 10, 2026
Following promising obesity data for oral GLP-1 agonist ASC30, Ascletis unveiled data with a subcutaneous formulation showing efficacy as a monthly injection and possibly quarterly maintenance use.
Scrip - March 10, 2026
Denali ‘Moving In A Positive Direction’ With FDA Toward Hunter Drug Action Date
The BLA for the company’s enzyme replacement therapy tividenofusp alfa has an April 5 action date, following on the heels of a complete response letter Regenxbio’s Hunter syndrome gene therapy.
Scrip - March 10, 2026
The BLA for the company’s enzyme replacement therapy tividenofusp alfa has an April 5 action date, following on the heels of a complete response letter Regenxbio’s Hunter syndrome gene therapy.
Scrip - March 10, 2026
Vertex Ratchets Up Competition In IgAN With Povetacicept Phase III Win
Povetacicept’s Phase III results strengthen Vertex’s push to expand beyond cystic fibrosis, with the company expected to complete the drug’s rolling submission by the end of March.
Scrip - March 10, 2026
Povetacicept’s Phase III results strengthen Vertex’s push to expand beyond cystic fibrosis, with the company expected to complete the drug’s rolling submission by the end of March.
Scrip - March 10, 2026
AbbVie Posts Encouraging Early-Stage Data For Amylin Analog ABBV-295
Phase I data for the long-acting amylin analog, which analysts touted as encouraging, highlights AbbVie's potential diversification beyond immunology and inflammation.
Scrip - March 10, 2026
Phase I data for the long-acting amylin analog, which analysts touted as encouraging, highlights AbbVie's potential diversification beyond immunology and inflammation.
Scrip - March 10, 2026
Our Work Here Is Done: BioNTech Founders Moving On To Next Start-Up
Co-founders Ugur Sahin and Özlem Türeci will depart BioNTech to work on a new mRNA spin-out company, but the announcement has left investors uncertain about the German firm’s future
Scrip - March 10, 2026
Co-founders Ugur Sahin and Özlem Türeci will depart BioNTech to work on a new mRNA spin-out company, but the announcement has left investors uncertain about the German firm’s future
Scrip - March 10, 2026
Stock Watch: Tensions In Tough Times For Bayer
Geopolitical events overshadowed Bayer’s financial results announcement, as was also the case for its peers. But Bayer’s history of acquisition and slow portfolio rejuvenation compound the clouds over its investment proposition.
Scrip - March 10, 2026
Geopolitical events overshadowed Bayer’s financial results announcement, as was also the case for its peers. But Bayer’s history of acquisition and slow portfolio rejuvenation compound the clouds over its investment proposition.
Scrip - March 10, 2026
ExThera Medical And Exec Face Legal Consequences After Deaths
ExThera Medical is facing legal trouble after two patients died following treatment with its blood filtration device. The company's former chief regulatory officer has pled guilty to failing to report adverse events, while ExThera signed a deferred prosecution alert and agreed to pay $6.45m.
Medtech Insight - March 10, 2026
ExThera Medical is facing legal trouble after two patients died following treatment with its blood filtration device. The company's former chief regulatory officer has pled guilty to failing to report adverse events, while ExThera signed a deferred prosecution alert and agreed to pay $6.45m.
Medtech Insight - March 10, 2026
Vitestro Raises $70M In Series B To Expand Autonomous Blood-Draw Robot In Europe, Eyes US Approval
Vitestro raised an oversubscribed $70M Series B to scale its autonomous blood-drawing system across the Netherlands and expand into Europe. The CE-marked robot has been tested in more than 10,000 patients, and the company is pursuing FDA clearance to enter the US market.
Medtech Insight - March 10, 2026
Vitestro raised an oversubscribed $70M Series B to scale its autonomous blood-drawing system across the Netherlands and expand into Europe. The CE-marked robot has been tested in more than 10,000 patients, and the company is pursuing FDA clearance to enter the US market.
Medtech Insight - March 10, 2026
Medtronic Bolsters Neurovascular Portfolio With $550M Scientia Buy
This acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.
Medtech Insight - March 10, 2026
This acquisition is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and accretive thereafter.
Medtech Insight - March 10, 2026
As Refund Claims Mount, Interest On IEEPA Tariff Payments Equals $650M A Month, $10Bn For 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
US Court of International Trade expects by March 12 to receive from Customs and Border Protection a “short report describing the progress” it “has made toward the development of a process to issue refunds of IEEPA duties paid with interest.”
HBW Insight - March 11, 2026
Henkel Buys Not Your Mother’s, Aveeno Collaborates With Mayo Clinic; Beauty Deals Roundup
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
Henkel Corp. plans to purchase DeMert Brands, owner of Not Your Mother’s hair care brand, from Main Post Partners for an undisclosed price, while KYT Group is purchasing Glo Skin Beauty and Aveeno has entered into a three-year collaboration with the Mayo Clinic; Beauty Deals Roundup
HBW Insight - March 11, 2026
Actelion Settles Tracleer Antitrust Case For $65m Ahead Of Trial
A proposed settlement would resolve claims that Actelion used REMS restrictions to block generic rivals from accessing Tracleer samples, allegedly delaying competition and inflating prices for insurers and other payors.
Generics Bulletin - March 10, 2026
A proposed settlement would resolve claims that Actelion used REMS restrictions to block generic rivals from accessing Tracleer samples, allegedly delaying competition and inflating prices for insurers and other payors.
Generics Bulletin - March 10, 2026
‘The Future Is Bright For Physician Adoption And Patient Access’ – Cardinal On US Biosimilar Trends
As the US biosimilars market continues to evolve, Cardinal Health’s director of biosimilars Dracey Poore talks to Generics Bulletin for an exclusive Q&A.
Generics Bulletin - March 10, 2026
As the US biosimilars market continues to evolve, Cardinal Health’s director of biosimilars Dracey Poore talks to Generics Bulletin for an exclusive Q&A.
Generics Bulletin - March 10, 2026
Shilpa Biologicals To Enter Latin America With SteinCares Biosimilars Pact
Deal pairs SteinCares’ regional commercialization platform with Shilpa Biologicals’ development and manufacturing capabilities for an undisclosed biosimilar.
Generics Bulletin - March 10, 2026
Deal pairs SteinCares’ regional commercialization platform with Shilpa Biologicals’ development and manufacturing capabilities for an undisclosed biosimilar.
Generics Bulletin - March 10, 2026
Sandoz Splits Out Biosimilars And Generics With New Business Structure
Sandoz has unveiled a major reorganization of its generics and biosimilars operations into two distinct businesses, bringing in Ferring and Merck veteran Armin Metzger to lead a new global biosimilars unit while at the same time assigning existing executives to generics roles.
Generics Bulletin - March 10, 2026
Sandoz has unveiled a major reorganization of its generics and biosimilars operations into two distinct businesses, bringing in Ferring and Merck veteran Armin Metzger to lead a new global biosimilars unit while at the same time assigning existing executives to generics roles.
Generics Bulletin - March 10, 2026
‘The Pirates All Know Where The Treasure Is’ – Staying Ahead Of The Competition In US Biosimilars
At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.
In Vivo - March 10, 2026
At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.
In Vivo - March 10, 2026